HK1247615A1 - 作為治療血栓形成的因子xia抑制劑的氧代吡啶衍生物 - Google Patents

作為治療血栓形成的因子xia抑制劑的氧代吡啶衍生物

Info

Publication number
HK1247615A1
HK1247615A1 HK18107027.2A HK18107027A HK1247615A1 HK 1247615 A1 HK1247615 A1 HK 1247615A1 HK 18107027 A HK18107027 A HK 18107027A HK 1247615 A1 HK1247615 A1 HK 1247615A1
Authority
HK
Hong Kong
Prior art keywords
thrombosis
oxo
pyridine
derivatives
treatment
Prior art date
Application number
HK18107027.2A
Other languages
English (en)
Chinese (zh)
Inventor
Susanne Röhrig
Henrik Teller
Stefan Heitmeier
Karl-Heinz Schlemmer
Jan Stampfuβ
Alexander Hillisch
Adrian Tersteegen
Nunez Eloisa Jimenez
Original Assignee
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG
Publication of HK1247615A1 publication Critical patent/HK1247615A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/69—Two or more oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Ophthalmology & Optometry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
HK18107027.2A 2015-03-19 2018-05-30 作為治療血栓形成的因子xia抑制劑的氧代吡啶衍生物 HK1247615A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15159829 2015-03-19
PCT/EP2016/055496 WO2016146606A1 (de) 2015-03-19 2016-03-15 Oxopyridin-derivate als faktor xia hemmer zur behandlung von thrombose

Publications (1)

Publication Number Publication Date
HK1247615A1 true HK1247615A1 (zh) 2018-09-28

Family

ID=52736868

Family Applications (1)

Application Number Title Priority Date Filing Date
HK18107027.2A HK1247615A1 (zh) 2015-03-19 2018-05-30 作為治療血栓形成的因子xia抑制劑的氧代吡啶衍生物

Country Status (7)

Country Link
US (1) US20190119213A1 (US20070167479A1-20070719-C00034.png)
EP (1) EP3271332A1 (US20070167479A1-20070719-C00034.png)
JP (1) JP2018509426A (US20070167479A1-20070719-C00034.png)
CN (1) CN107428689A (US20070167479A1-20070719-C00034.png)
CA (1) CA2979937A1 (US20070167479A1-20070719-C00034.png)
HK (1) HK1247615A1 (US20070167479A1-20070719-C00034.png)
WO (1) WO2016146606A1 (US20070167479A1-20070719-C00034.png)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10077265B2 (en) * 2014-09-24 2018-09-18 Bayer Pharma Aktiengesellschaft Substituted oxopyridine derivatives
US11884660B2 (en) 2018-04-10 2024-01-30 Bayer Pharma Aktiengesellschaft Substituted oxopyridine derivative
BR112021000439A2 (pt) * 2018-07-19 2021-04-06 Jiangsu Hengrui Medicine Co., Ltd. Método para preparar o inibidor do fator de coagulação xia e intermediário do mesmo
TW202039510A (zh) * 2018-12-21 2020-11-01 德商拜耳廠股份有限公司 經取代的側氧基吡啶衍生物
CA3124296A1 (en) 2018-12-21 2020-06-25 Bayer Aktiengesellschaft Substituted oxopyridine derivatives
CN116947818B (zh) * 2023-09-18 2023-12-19 成都施贝康生物医药科技有限公司 一种氧代吡啶类化合物、中间体及其制备方法和用途

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200813017A (en) * 2006-05-05 2008-03-16 Millennium Pharm Inc Factor XA inhibitors
WO2014160592A2 (en) * 2013-03-27 2014-10-02 Merck Sharp & Dohme Corp. FACTOR XIa INHIBITORS
TWI633089B (zh) * 2013-03-28 2018-08-21 拜耳製藥股份有限公司 經取代的酮基吡啶衍生物
EP3063150B1 (de) * 2013-10-30 2017-11-22 Bayer Pharma Aktiengesellschaft Substituierte oxopyridin-derivate
WO2016046156A1 (de) * 2014-09-24 2016-03-31 Bayer Pharma Aktiengesellschaft Substituierte oxopyridin-derivate
JP6517925B2 (ja) * 2014-09-24 2019-05-22 バイエル ファーマ アクチエンゲゼルシャフト 置換されたオキソピリジン誘導体
US10077265B2 (en) * 2014-09-24 2018-09-18 Bayer Pharma Aktiengesellschaft Substituted oxopyridine derivatives
US10138236B2 (en) * 2014-09-24 2018-11-27 Bayer Pharma Aktiengesellschaft Factor xia-inhibiting pyridobenzazepine and pyridobenzazocine derivatives
WO2016046159A1 (de) * 2014-09-24 2016-03-31 Bayer Pharma Aktiengesellschaft Substituierte oxopyridin-derivate
EP3197872B1 (de) * 2014-09-24 2019-01-30 Bayer Pharma Aktiengesellschaft (2h)-2-oxopyridine als faktor xia-inhibitoren zur behandlung von thrombotischen erkrankungen
JO3703B1 (ar) * 2015-07-09 2021-01-31 Bayer Pharma AG مشتقات أوكسوبيريدين مستبدلة
WO2017037051A1 (de) * 2015-09-04 2017-03-09 Bayer Pharma Aktiengesellschaft Substituierte oxopyridin-derivate
RU2742771C2 (ru) * 2016-08-31 2021-02-10 Цзянсу Хэнжуй Медицин Ко., Лтд. Производное оксопиколинамида, способ его получения и его фармацевтическое применение

Also Published As

Publication number Publication date
CA2979937A1 (en) 2016-09-22
CN107428689A (zh) 2017-12-01
JP2018509426A (ja) 2018-04-05
WO2016146606A1 (de) 2016-09-22
US20190119213A1 (en) 2019-04-25
EP3271332A1 (de) 2018-01-24

Similar Documents

Publication Publication Date Title
IL259560A (en) Inhibitors of the menin-mll interaction
HRP20181772T1 (hr) Spoj za obradu gnojiva koje sadrži ureu
HK1251614A1 (zh) 用於惡性腫瘤的治療的方法
IL253945A0 (en) kdm1a inhibitors to treat the disease
EP3359171C0 (en) USING AKKERMANSIA MUCINIPHILA TO TREAT INFLAMMATORY CONDITIONS
HK1249097A1 (zh) 作為pde1抑制劑的咪唑並三嗪酮
HK1252098A1 (zh) 作為pde1抑制劑的咪唑並吡嗪酮
HK1244217A1 (zh) 用於治療蛋白質病的方法
HK1247615A1 (zh) 作為治療血栓形成的因子xia抑制劑的氧代吡啶衍生物
PL3261726T3 (pl) Kompozycja do leczenia trądziku
GB201521059D0 (en) Inhibitors of metallo-beta-lactamases
HK1247558A1 (zh) 塞內可瑞偉洛克(cenicriviroc)用於治療纖維化
IL256537A (en) Inhibitors for treating uveal melanoma
IL255498A (en) Treatment of pruritus
PL3292226T3 (pl) Sposób obróbki szlamu zawierającego żelazo
PT2965754T (pt) Método de tratamento de deficiência de ferro
GB201512139D0 (en) Methods of treatment
PT3524255T (pt) Composição para o tratamento do acne
GB201511017D0 (en) Method of treatment